The time it takes to feel results from a B-12 injection can vary depending on the individual and the severity of the deficiency
This reduces variables that can influence both safety and outcomes compared with self-managed use
Standard escalation protocol The most widely used escalation schedule for compounded tirzepatide B12 formulations follows this structure

related full-length recombinant thymosin beta-4 (a different formulation than the marketed TB-500 fragment) has also been examined in small human studies for cardiac and dermatologic indications Examined in preclinical models, including diabetic rat Achilles tendon and rat ligament-injury studies, for actin-binding, cell-migration, and angiogenic activity that researchers have proposed as a mechanism for tendon and ligament repair, though this literature remains comparatively sparse for musculoskeletal applications specifically Known risks and side effects: Because TB-500 is manufactured and sold without FDA oversight as a "research chemical," independent testing and industry reporting describe wide variability in purity (with some products measured well below labeled potency) and contamination with heavy metals or bacterial byproducts, unlike pharmaceutical-grade recombinant thymosin beta-4 used in registered clinical trials Thymosin beta-4's core mechanisms, angiogenesis and cell migration, are also pathways exploited by tumors

Competitive radioligand binding assays reveal concentration-dependent displacement curves, indicating specific receptor engagement at nanomolar concentrations
Enhanced Metabolism